For Healthcare Professionals

For Healthcare Professionals

As a professional, Eisai aims to support you in the treatment of your patients. In this section you will find information, including: Medsafe Data sheets, and Consumer Medicines Informations (CMIs).

If you require further information, please contact Eisai Medical Information at Medinfo_NewZealand@eisai.net

Please follow the links to find further details of the medicines available in New Zealand.

Adverse events should also be reported to Eisai New Zealand Ltd.
email: Safety_NewZealand@eisai.net
tel: +61 3 9832 9100
tel: 0800 00 52 06

Healthcare Professional

Oncology

Neurology

Halaven® (eribulin mesilate) – Prescription Medicine, unfunded (prescription charge will apply). Available in 2ml vial containing 1mg eribulin mesilate. INDICATIONS: Halaven is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless these are contraindicated. Halaven is indicated for the treatment of patients with unresectable liposarcoma who have received prior chemotherapy for advanced or metastatic disease. TAPS DA 2416MVR. 0424.

Lenvima® (lenvatinib mesilate) – Prescription Medicine, unfunded (prescription charge will apply). Available in 4 mg and 10 mg hard capsules. INDICATIONS: Lenvima is used for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine refractory differentiated thyroid cancer and for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). It is also used in combination with pembrolizumab for the treatment of patients with advanced endometrial carcinoma who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. Lenvima is also used in combination with pembrolizumab, for first-line treatment of patients with advanced renal cell carcinoma (RCC) or in combination with everolimus, for the treatment of adult patients with advanced RCC whose disease has progressed following one prior vascular endothelial growth factor targeted therapy. TAPS DA 2416MVR. 0522.

Fycompa® (perampanel) – Prescription Medicine, unfunded (prescription charge will apply). Available as film-coated tablets: 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg. Oral suspension 2 mg/4 mL. INDICATIONS: Adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients from 4 years of age with epilepsy. Adjunctive treatment of primary generalised tonic-clonic seizures in patients from 7 years of age with idiopathic generalised epilepsy. TAPS DA 2416MVR. 1121.

Inovelon® (rufinamide) – Prescription Medicine, unfunded (prescription charge will apply). Available as film coated tablets: 200 mg and 400 mg. INDICATION: Adjunctive treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older. TAPS DA 2416MVR. 0620.

Before prescribing any of the products listed above, review the relevant Data Sheet for information on dosage, contraindications, precautions, interactions and adverse effects, available at www.medsafe.govt.nz.

Halaven®, Lenvima®, Fycompa® and Inovelon® are registered trademarks of the Eisai Group, whose affiliate company in New Zealand is Eisai New Zealand Limited, c/o Simpson Grierson, Level 27, 88 Shortland Street, Auckland Central, Auckland, 1010.